Related Experiment Video
Updated: Jun 26, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Microtubule dynamics as a target in oncology
April L Risinger1, Francis J Giles, Susan L Mooberry
1Department of Pharmacology, The University of Texas Health Science Center, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Abstract:
Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In this review, we discuss the molecular mechanisms as well as preclinical and clinical results for a variety of microtubule-targeting agents in various stages of development. We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.
Insights
Microtubule-targeting agents, including taxanes and vinca alkaloids, are crucial cancer therapies. This review evaluates their development, efficacy, and toxicity for future therapeutic potential.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Microtubule dynamics are critical targets in cancer therapy.
- Taxanes and vinca alkaloids have long been used against leukemias and solid tumors.
- Novel microtubule-targeting agents are continually being developed and evaluated.
Purpose of the Study:
- To review the molecular mechanisms of microtubule-targeting agents.
- To analyze preclinical and clinical results of various agents.
- To assess the future development potential of these drugs based on efficacy and safety.
Main Methods:
- Literature review of molecular mechanisms.
- Analysis of preclinical data in animal models.
- Evaluation of clinical trial outcomes.
- Assessment of drug availability, efficacy, and toxicity profiles.
Main Results:
- Established agents like taxanes and vinca alkaloids remain important.
- Newer agents show promise, with some approved (e.g., ixabepilone).
- Several agents with preclinical success failed in clinical trials due to inefficacy or toxicity.
Conclusions:
- Continued research into microtubule-targeting agents is vital for cancer treatment.
- Careful evaluation of efficacy, toxicity, and availability is necessary for drug development.
- Optimizing microtubule-targeting agents may lead to improved cancer therapies.
Related Concept Videos
Destabilization of Microtubules
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Microtubule Formation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

